|Articles|September 22, 2016

EpiPen Controversy: Mylan CEO Faces Congressional Committee

September 22, 2016

Mylan CEO Heather Bresch appeared before the House Committee on Oversight and Government Reform on Sept. 21, 2016 to explain the company’s decision to increase the price of EpiPen more than 400%. The meeting comes after multiple members of Congress raised concerns about the price of the life-saving drug, which is used to treat anaphylaxis.

In her pre-released testimony, Bresch attempted to clarify exactly how much money Mylan makes off each EpiPen sale.

For the rest of this news release, see Pharmaceutical Technology.

Newsletter

Lead with insight with the Pharmaceutical Executive newsletter, featuring strategic analysis, leadership trends, and market intelligence for biopharma decision-makers.

Subscribe Now!

EpiPen Controversy: Mylan CEO Faces Congressional Committee

Newsletter

Related Content

The Hidden Gem: Turn AI Roleplay Data into Commercial Intelligence

What Does Infinitus Think About the Relationship Between AI Automation and Human Oversight?

What Does a Truly Ai-Native Patient Access Infrastructure Look Like in 2026?

What Governance Resets Should Pharma Companies Take in Response to AI?

What Pharma Marketers Need to Know About Recent Gartner Predictions About AI and What It Means to Them

Trending on PharmExec

Bayer Shares Briefly Dip After Activist Investor Offloads Millions of Dollars in Company Stock

Pharmaceutical Executive Daily: FDA Issues Warning Letter to ImmunityBio

Pharma M&A Roundup: Merck to Acquire Terns Pharmaceuticals, Shionogi to Acquire 50% of Apnimed’s Ownership of Shionogi-Apnimed Sleep Science

FDA Sends Warning Letter to ImmunityBio for Misleading Claims in Advertisement

How Have Recent Regulatory Actions Impacted the Rare Disease Space?